688238 和元生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-9.665-6.0492.5416.14120.215
总资产报酬率 ROA (%)-7.657-5.0172.0884.90616.380
投入资产回报率 ROIC (%)-8.618-5.5852.3025.40918.397

边际利润分析
销售毛利率 (%)-21.945-6.55244.41151.33658.109
营业利润率 (%)-102.648-75.90014.31823.84762.647
息税前利润/营业总收入 (%)-102.560-83.8864.86520.61962.778
净利润/营业总收入 (%)-103.471-62.40813.47621.28263.939

收益指标分析
经营活动净收益/利润总额(%)94.384100.11285.56677.94912.279
价值变动净收益/利润总额(%)0.6890.7435.5105.85882.055
营业外收支净额/利润总额(%)0.0620.101-0.201-0.020-0.071

偿债能力分析
流动比率 (X)2.5442.9527.8365.45310.389
速动比率 (X)2.2672.6957.4845.13110.080
资产负债率 (%)20.61820.93813.00927.36710.418
带息债务/全部投入资本 (%)8.3506.4201.0508.5570.929
股东权益/带息债务 (%)1,059.5041,398.7449,037.552956.19810,336.979
股东权益/负债合计 (%)385.083377.573668.693265.397859.884
利息保障倍数 (X)-675.95110.606-0.516-6.398358.316

营运能力分析
应收账款周转天数 (天)101.534129.20465.89536.96441.571
存货周转天数 (天)96.995120.835121.92096.105105.545